NATIONAL CANCER CENTER;KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY;국립암센터;한국화학연구원
发明人:
KIM, Kyungtae,김경태,LEE, Joo-Youn,이주연,LEE, Su-Hyung,이수형,LEE, Byung Il,이병일,PARK, Joong-Won,박중원,LEE, Eun Sook,이은숙,LEE, Sang Jin,이상진,BONG, Seoung Min,봉승민,KIM, Jin Sook,김진숙,PARK, Minji,박민지,YOON, Eun-Kyung,윤
申请号：
KRKR2018/014944
公开号：
WO2020/111325A1
申请日:
2018.11.29
申请国别(地区):
KR
年份:
2020
代理人:
摘要：
The present invention relates to a pharmaceutical composition for preventing, treating or alleviating cancer, containing an activation Inhibitor of PLK1 as an active ingredient, and a compound according to the present invention selectively binds to PBD of PLK1, thereby having advantages of high selectivity and binding affinity for PLK1 and low toxicity. Therefore, a PLK1 activation inhibitor compound according to the present invention can be effectively used as an anticancer agent by inhibiting the growth of various cancer cells, and can be expected to exhibit synergistic effects with existing developed anticancer agents through co-administration, in addition to individual administration thereof.La présente invention concerne une composition pharmaceutique destinée à prévenir, traiter ou soulager le cancer, contenant un inhibiteur de l'activation de PLK1 en tant que principe actif, et un composé selon la présente invention se lie sélectivement à PBD de PLK1, ce qui présente les avantages d'une sélectivité et d'une affinité de liaison à PLK1 élevées et d'une faible toxicité. Par conséquent, le composé inhibiteur de l'activation de PLK1 selon la présente invention peut être utilisé efficacement en tant qu'agent anticancéreux par inhibition de la croissance de diverses cellules cancéreuses et peut, en prévision, présenter des effets synergiques avec des agents anticancéreux existants par co-administration en plus de son administration individuelle.본 발명은 PLK1의 활성 억제제를 유효성분으로 포함하는 암 예방, 치료 또는 개선용 약학적 조성물에 관한 것으로 본 발명에 따른 상기 화합물은 PLK1의 PBD에 선택적으로 결합함으로써, PLK1에 대한 높은 선택성과 결합친화성, 및 저독성의 이점을 갖는다. 따라서, 본 발명에 따른 PLK1 활성 억제제 화합물은 다양한 암세포의 성장을 저해함으로써 항암제로 유용하게 이용될 수 있을 것이며, 단독투여 이외에도 기존에 개발된 항암제와의 병용투여를 통한 시너지효과를 기대할 수 있다.
